Page last updated: 2024-10-25

deferoxamine and Dementia

deferoxamine has been researched along with Dementia in 17 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.

Research Excerpts

ExcerptRelevanceReference
"Ultrafiltration experiments, using Amicon membranes with molecular weight exclusions of 1,000, 10,000 and 30,000 daltons, have revealed that Desferal, both in vitro and in vivo, markedly increases aluminum ultrafilterability in plasma from patients with dialysis dementia."7.67Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. ( Agness, C; Gonick, HC; Khalil-Manesh, F, 1989)
"Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)."5.27Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988)
"Ultrafiltration experiments, using Amicon membranes with molecular weight exclusions of 1,000, 10,000 and 30,000 daltons, have revealed that Desferal, both in vitro and in vivo, markedly increases aluminum ultrafilterability in plasma from patients with dialysis dementia."3.67Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. ( Agness, C; Gonick, HC; Khalil-Manesh, F, 1989)
"We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate."3.67Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. ( Corwin, HL; Mayor, GH; Sprague, SM; Tanner, CM; Wilson, RS, 1986)
" Twenty-four patients, 15 with dialysis osteomalacia and nine with clinically apparent secondary hyperparathyroidism, had serum aluminum levels measured before and after a standard infusion of a chelating agent, deferoxamine (DFO)."3.67Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? ( Brown, P; Cordy, PE; Hodsman, AB; Hood, SA, 1985)
"Five patients with dialysis encephalopathy were transferred to deionized water; all died after a variable period, 4 of progressive dementia."1.27The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. ( Bell, P; Meyers, AM; Milne, FJ; Sharf, B, 1983)
"Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)."1.27Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-199010 (58.82)18.7374
1990's3 (17.65)18.2507
2000's2 (11.76)29.6817
2010's1 (5.88)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Mielke, N1
Johnson, S1
Bahl, A1
Fadladdin, YAJ1
Xue, M1
Zhang, X1
Chen, J1
Liu, F1
Xu, J1
Xie, J1
Yang, Y1
Yu, W1
Qiu, H1
Xue, J1
Jiang, J1
Liu, Y2
Shallom, SJ1
Zelazny, AM1
Giri, AR1
Kaur, N1
Yarrarapu, SNS1
Rottman Pietrzak, KA1
Santos, C1
Lowman, PE1
Niaz, S1
Franco, PM1
Sanghavi, DK1
Zhu, D1
Liang, R1
Li, Z2
Cheng, L1
Ren, J1
Guo, Y1
Wang, M1
Chai, H1
Niu, Q1
Yang, S1
Bai, J1
Yu, H1
Zhang, H1
Qin, X1
Sahrakorpi, N1
Engberg, E1
Stach-Lempinen, B1
Tammelin, TH1
Kulmala, J1
Roine, RP1
Koivusalo, SB1
Cheng, W1
Pang, H1
Campen, MJ1
Zhang, J2
Li, Y1
Gao, J1
Ren, D1
Ji, X1
Rothman, N1
Lan, Q1
Zheng, Y1
Leng, S1
Hu, Z1
Tang, J1
Dong, Q1
Song, N1
Qin, N1
Chen, C1
Sun, X1
Easton, J1
Mulder, H1
Plyler, E1
Neale, G1
Walker, E1
Li, Q1
Ma, X1
Chen, X1
Huang, IC1
Yasui, Y1
Ness, KK1
Hudson, MM1
Robison, LL1
Wang, Z1
Subota, A1
Spotswood, N1
Roach, M1
Goodarzi, Z1
Holroyd-Leduc, J1
Park, EA1
Graves, SA1
Menda, Y1
Tseng, YJ1
Chen, CH1
Chen, WK1
Dong-Zong, H1
Kinugasa, E1
Yamamoto, M1
Fukui, T1
Kashiwagi, T1
Kurihara, S1
Shore, D1
Wyatt, RJ1
Hood, SA2
Clark, WF1
Hodsman, AB2
Bolton, CF1
Cordy, PE2
Anderson, C1
Leung, F1
Milne, FJ1
Sharf, B1
Bell, P1
Meyers, AM1
Cutler, P1
Ogura, Y1
Yokoyama, K1
Ohara, M1
Verbeelen, D1
Khalil-Manesh, F1
Agness, C1
Gonick, HC1
McLachlan, DR1
Kruck, TP1
VanBerkum, MF1
Sherrard, DJ1
Walker, JV1
Boykin, JL1
Sprague, SM1
Corwin, HL1
Wilson, RS1
Mayor, GH1
Tanner, CM1
Swartz, RD1
Weiland, P1
Köhler, M1
Glatzel, E1
Brown, P1

Reviews

6 reviews available for deferoxamine and Dementia

ArticleYear
    Lancet regional health. Americas, 2022, Volume: 8

    Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas

2022
[Dialysis encephalopathy].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 6

    Topics: Aluminum; Deferoxamine; Dementia; Diagnosis, Differential; Dialysis; Dialysis Solutions; Drug Contam

2004
[Aluminum and iron deposition in dialysis patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 6

    Topics: Aluminum; Aluminum Hydroxide; Anemia; Bone Diseases, Metabolic; Contraindications; Deferoxamine; Dem

2004
Aluminum and Alzheimer's disease.
    The Journal of nervous and mental disease, 1983, Volume: 171, Issue:9

    Topics: Aluminum; Alzheimer Disease; Animals; Brain Chemistry; Cell Nucleus; Cooking and Eating Utensils; De

1983
Aluminum and neurodegenerative disease: therapeutic implications.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1985, Volume: 6, Issue:5

    Topics: Aluminum; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Calcium; Deferoxamine; D

1985
Deferoxamine and aluminum removal.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1985, Volume: 6, Issue:5

    Topics: Aluminum; Bone and Bones; Chelating Agents; Deferoxamine; Dementia; Humans; Iron; Osteomalacia; Peri

1985

Other Studies

11 other studies available for deferoxamine and Dementia

ArticleYear
Hand warmer related corrosive injury.
    Clinical toxicology (Philadelphia, Pa.), 2011, Volume: 49, Issue:9

    Topics: Accidents, Home; Aged, 80 and over; Aluminum Silicates; Burns, Chemical; Charcoal; Deferoxamine; Dem

2011
Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
    American journal of nephrology, 1984, Volume: 4, Issue:6

    Topics: Aluminum; Biopsy; Bone and Bones; Deferoxamine; Dementia; Female; Glomerulonephritis; Hemodialysis,

1984
The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Clinical nephrology, 1983, Volume: 20, Issue:4

    Topics: Adult; Aged; Aluminum; Bone Diseases; Brain Diseases; Deferoxamine; Dementia; Electroencephalography

1983
Iron overload and psychiatric illness.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1994, Volume: 39, Issue:1

    Topics: Adult; Aged; Anxiety Disorders; Carrier Proteins; Deferoxamine; Dementia; Depressive Disorder; Diagn

1994
[Dialysis encephalopathy].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50 Suppl

    Topics: Anticonvulsants; Apraxias; Deferoxamine; Dementia; Electroencephalography; Humans; Kidney Failure, C

1992
Aluminum toxicity.
    Acta clinica Belgica, 1991, Volume: 46, Issue:2

    Topics: Aluminum; Anemia; Animals; Deferoxamine; Dementia; Disease Models, Animal; Humans; Kidney Failure, C

1991
Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration.
    Nephron, 1989, Volume: 52, Issue:4

    Topics: Aluminum; Carrier Proteins; Deferoxamine; Dementia; Humans; Molecular Weight; Renal Dialysis; Ultraf

1989
Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1988, Volume: 12, Issue:2

    Topics: Adult; Aluminum; Bone Diseases; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Mal

1988
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Archives of internal medicine, 1986, Volume: 146, Issue:10

    Topics: Aluminum; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Middle Aged; Myoclonus; R

1986
[Successful treatment of progressive dialysis encephalopathy. Case report].
    Zeitschrift fur Urologie und Nephrologie, 1985, Volume: 78, Issue:7

    Topics: Aluminum; Deferoxamine; Dementia; Electroencephalography; Evoked Potentials; Female; Humans; Kidney

1985
Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    The Journal of laboratory and clinical medicine, 1985, Volume: 106, Issue:6

    Topics: Adult; Aluminum; Biopsy; Bone and Bones; Deferoxamine; Dementia; Humans; Hyperparathyroidism, Second

1985